$8.16
7.80% today
Nasdaq, Apr 03, 07:19 pm CET
ISIN
US88025U1097
Symbol
TXG
Sector
Industry

10x Genomics Inc - Ordinary Shares - Class A Target price 2025 - Analyst rating & recommendation

10x Genomics Inc - Ordinary Shares - Class A Classifications & Recommendation:

Buy
40%
Hold
50%
Sell
10%

10x Genomics Inc - Ordinary Shares - Class A Price Target

Target Price $15.73
Price $8.85
Potential
Number of Estimates 15
15 Analysts have issued a price target 10x Genomics Inc - Ordinary Shares - Class A 2026 . The average 10x Genomics Inc - Ordinary Shares - Class A target price is $15.73. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 20 analysts: 8 Analysts recommend 10x Genomics Inc - Ordinary Shares - Class A to buy, 10 to hold and 2 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the 10x Genomics Inc - Ordinary Shares - Class A stock has an average upside potential 2026 of . Most analysts recommend the 10x Genomics Inc - Ordinary Shares - Class A stock at Hold.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 610.79 610.52
1.28% 0.04%
EBITDA Margin -24.31% -26.18%
4.95% 7.69%
Net Margin -30.43% -30.19%
29.37% 0.80%

17 Analysts have issued a sales forecast 10x Genomics Inc - Ordinary Shares - Class A 2025 . The average 10x Genomics Inc - Ordinary Shares - Class A sales estimate is

$611m
Unlock
. This is
0.04% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$621m 1.64%
Unlock
, the lowest is
$597m 2.31%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $611m 1.28%
2025
$611m 0.04%
Unlock
2026
$666m 9.15%
Unlock
2027
$726m 8.98%
Unlock
2028
$791m 8.95%
Unlock
2029
$833m 5.32%
Unlock

11 Analysts have issued an 10x Genomics Inc - Ordinary Shares - Class A EBITDA forecast 2025. The average 10x Genomics Inc - Ordinary Shares - Class A EBITDA estimate is

$-160m
Unlock
. This is
7.64% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-134m 9.47%
Unlock
, the lowest is
$-229m 54.22%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-148m 6.17%
2025
$-160m 7.64%
Unlock
2026
$-120m 25.23%
Unlock
2027
$-77.3m 35.33%
Unlock
2028
$-7.6m 90.12%
Unlock

EBITDA Margin

2024 -24.31% 4.95%
2025
-26.18% 7.69%
Unlock
2026
-17.93% 31.51%
Unlock
2027
-10.64% 40.66%
Unlock
2028
-0.96% 90.98%
Unlock

18 10x Genomics Inc - Ordinary Shares - Class A Analysts have issued a net profit forecast 2025. The average 10x Genomics Inc - Ordinary Shares - Class A net profit estimate is

$-184m
Unlock
. This is
0.83% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-139m 25.19%
Unlock
, the lowest is
$-226m 21.71%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-186m 30.28%
2025
$-184m 0.83%
Unlock
2026
$-142m 22.95%
Unlock
2027
$-107m 24.68%
Unlock
2028
$-95.4m 10.84%
Unlock
2029
$-138m 44.87%
Unlock

Net Margin

2024 -30.43% 29.37%
2025
-30.19% 0.80%
Unlock
2026
-21.32% 29.38%
Unlock
2027
-14.73% 30.91%
Unlock
2028
-12.06% 18.13%
Unlock
2029
-16.58% 37.48%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -1.52 -1.51
30.28% 0.66%
P/E negative
EV/Sales 1.26

18 Analysts have issued a 10x Genomics Inc - Ordinary Shares - Class A forecast for earnings per share. The average 10x Genomics Inc - Ordinary Shares - Class A EPS is

$-1.51
Unlock
. This is
0.66% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-1.14 25.00%
Unlock
, the lowest is
$-1.85 21.71%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-1.52 30.28%
2025
$-1.51 0.66%
Unlock
2026
$-1.16 23.18%
Unlock
2027
$-0.87 25.00%
Unlock
2028
$-0.78 10.34%
Unlock
2029
$-1.13 44.87%
Unlock

P/E ratio

Current -5.83 66.18%
2025
-5.87 0.69%
Unlock
2026
-7.62 29.81%
Unlock
2027
-10.12 32.81%
Unlock
2028
-11.35 12.15%
Unlock
2029
-7.83 31.01%
Unlock

Based on analysts' sales estimates for 2025, the 10x Genomics Inc - Ordinary Shares - Class A stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.26 81.33%
2025
1.26 0.30%
Unlock
2026
1.16 8.38%
Unlock
2027
1.06 8.24%
Unlock
2028
0.98 8.22%
Unlock
2029
0.93 5.06%
Unlock

P/S ratio

Current 1.77 75.48%
2025
1.77 0.05%
Unlock
2026
1.62 8.38%
Unlock
2027
1.49 8.24%
Unlock
2028
1.37 8.22%
Unlock
2029
1.30 5.05%
Unlock

Current 10x Genomics Inc - Ordinary Shares - Class A Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Citigroup
Locked
Locked
Locked Mar 04 2025
Barclays
Locked
Locked
Locked Feb 14 2025
Morgan Stanley
Locked
Locked
Locked Feb 14 2025
JP Morgan
Locked
Locked
Locked Feb 13 2025
Leerink Partners
Locked
Locked
Locked Feb 13 2025
Citigroup
Locked
Locked
Locked Feb 13 2025
Stifel
Locked
Locked
Locked Feb 13 2025
Analyst Rating Date
Locked
Citigroup:
Locked
Locked
Mar 04 2025
Locked
Barclays:
Locked
Locked
Feb 14 2025
Locked
Morgan Stanley:
Locked
Locked
Feb 14 2025
Locked
JP Morgan:
Locked
Locked
Feb 13 2025
Locked
Leerink Partners:
Locked
Locked
Feb 13 2025
Locked
Citigroup:
Locked
Locked
Feb 13 2025
Locked
Stifel:
Locked
Locked
Feb 13 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today